Rate My Professor Philip Newsome

Professor Philip Newsome is Professor of Hepatology in the Faculty of Life Sciences & Medicine at King’s College London. He earned his BSc (Hons) in Neuroscience in 1994, MBChB in 1995, PhD in Medicine in 2003 from the University of Birmingham, and Fellowship of the Royal College of Physicians of Edinburgh (FRCPE) in 2009. Previously at the University of Birmingham, he served as Honorary Professor of Experimental Hepatology, Director of the Centre for Liver and Gastrointestinal Research, Director of the NIHR Birmingham Biomedical Research Centre until June 2024, Director of the Innovate UK funded Midlands and Wales Advanced Therapy Treatment Centre, and Honorary Consultant Hepatologist. At King’s College London, he is Director of the Roger Williams Institute of Liver Studies, Director of the Roger Williams Institute of Hepatology, and Director of the King’s Health Partners Centre for Translational Medicine. He runs the metabolic services at the Liver Unit at King’s College Hospital London, managing a large multi-disciplinary clinic for patients with non-alcoholic fatty liver disease (NAFLD).

Professor Newsome’s research focuses on the role of cell therapy in liver injury, NAFLD now termed metabolic dysfunction-associated steatotic liver disease (MASLD), GLP-1 therapies, haematopoietic stem cell therapy in liver cirrhosis, and mesenchymal stromal cells in primary sclerosing cholangitis. He developed the FAST score for identifying at-risk NASH patients and co-led the global nomenclature change from NAFLD to MASLD. As Chief Investigator, he led randomised controlled trials of GLP-1 therapies in NAFLD published in The Lancet and The New England Journal of Medicine, the REALISTIC trial of haematopoietic stem cell therapy in liver cirrhosis published in Lancet Gastroenterology & Hepatology, and coordinates the MERLIN EU FP7 consortium trial of mesenchymal stromal cells in PSC. He chaired national guidelines for liver transplantation in NAFLD, sat on the NICE Guideline Development Group for NAFLD, led the UK multi-stakeholder guideline on abnormal liver blood tests, and contributed to the EASL–Lancet Liver Commission. He completed a term as Secretary General (President) of the European Association for the Study of the Liver, serves as National Clinical Lead for Advanced Therapy Treatment Centres, and is Senior Editor at the Journal of Hepatology. His awards include election as Fellow of the Academy of Medical Sciences and NIHR Senior Investigator (2024-2027). Key publications include 'A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis' (NEJM, 2024), 'The EASL–Lancet Liver Commission' (The Lancet, 2022), and 'Prognostic performance of the two-step clinical care pathway in metabolic dysfunction-associated steatotic liver disease' (Journal of Hepatology, 2025).